Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) EPS (Weighted Average and Diluted) (2019 - 2025)

Historic EPS (Weighted Average and Diluted) for Agios Pharmaceuticals (AGIO) over the last 10 years, with Q4 2025 value amounting to -$1.85.

  • Agios Pharmaceuticals' EPS (Weighted Average and Diluted) fell 632.18% to -$1.85 in Q4 2025 from the same period last year, while for Dec 2025 it was -$7.11, marking a year-over-year decrease of 16269.84%. This contributed to the annual value of -$7.12 for FY2025, which is 16116.84% down from last year.
  • Agios Pharmaceuticals' EPS (Weighted Average and Diluted) amounted to -$1.85 in Q4 2025, which was down 632.18% from -$1.78 recorded in Q3 2025.
  • Agios Pharmaceuticals' 5-year EPS (Weighted Average and Diluted) high stood at $26.95 for Q1 2021, and its period low was -$1.93 during Q2 2025.
  • Its 5-year average for EPS (Weighted Average and Diluted) is $0.88, with a median of -$1.56 in 2021.
  • Per our database at Business Quant, Agios Pharmaceuticals' EPS (Weighted Average and Diluted) soared by 411093.75% in 2021 and then tumbled by 35671.64% in 2023.
  • Over the past 5 years, Agios Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarter) stood at $0.07 in 2021, then soared by 923.5% to $0.67 in 2022, then plummeted by 356.72% to -$1.72 in 2023, then dropped by 1.16% to -$1.74 in 2024, then decreased by 6.32% to -$1.85 in 2025.
  • Its last three reported values are -$1.85 in Q4 2025, -$1.78 for Q3 2025, and -$1.93 during Q2 2025.